Beyond imaging PD-L1 using PET, several interesting biomarkers were introduced to molecular imaging in preclinical settings such as interferon-γ immuno-PET (89Zr-anti-IFN-γ) that allows imaging of activated lymphocytes inside tumour lesions [93]. This evidence concerns the gene IFNG and neoplasm.